Policy Comments
The priority legislative and regulatory issues that the Cancer Policy Institute focuses on are driven by policy pillars that are centered around the values, needs, and preferences of individuals impacted by cancer. We work in conjunction with patients, patient advocacy organizations, medical associations, and other stakeholders to advance policies aimed at improving access to, affordability of, and quality of care across the cancer continuum.
Recommendations for protecting patients’ access to care as the Medicaid continuous coverage requirements end.
Letter in response to the Senate HELP committee's RFI emphasizing the importance of including the patient perspective when considering the impact of the growing health care workforce shortages.
Letter outlining how the Affordable Care Act outlines has improved access to affordable healthcare and highlights ways to improve affordability.
Letter urging Congress to ensure that regulators at CMS create specific opportunities for patient advocates to participate in the regulatory process.
Letter to Congress requesting an increase in federal funding for domestic and global antimicrobial resistance (AMR) programs through the appropriations process.
Letter urging any efforts to change Medicaid’s current financing structure or add any barriers to coverage be rejected.
Letter expressing support for the Reducing Hereditary Cancer Act (H.R.1526/S.765) which would expand access to genetic testing for individuals with a history or suspected history of a hereditary cancer gene mutation and would expand coverage for risk-reduction.
Letters urging the inclusion of the PASTEUR Act in any moving legislative vehicle this year, including the reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA).
Letter in response to the National Committee for Quality Assurance's (NCQA) opportunity to comment on their ongoing work to address gaps in cancer screening and quality measurement for transgender, gender-diverse, and intersex populations.
Letter to HHS in response to the Medicare Program Contract Year 2024 Proposed Rule that addresses health equity in Medicare Advantage and utilization management requirements.